A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
Phase 2
Terminated
NCT06113328
| Condition | Non-segmental Vitiligo |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Merck Sharp & Dohme LLC |
|---|
| Status | Terminated |
|---|
| Enrollment | 169 participants |
|---|
| Interventions | MK-6194 |
|---|
| Start date | Nov 27, 2023 |
|---|
| Completion date | Mar 20, 2025 |
|---|
| Results posted | Mar 17, 2026 |
|---|
Summary
Researchers are looking for a new way to treat people with non-segmental vitiligo (NSV). The goal of this study is to learn about the safety of MK-6194 and how well people tolerate it. Researchers also want to learn if people who take MK-6194 have more of a decrease in the amount of vitiligo on their face compared to people who take placebo.
Percent Change From Baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24
Baseline and Week 24 · Percent change
| MK-6194 3 mg Q2W | -4.55 Percent change |
|---|
| MK-6194 3 mg Q4W | -12.13 Percent change |
|---|
| Placebo | -4.01 Percent change |
|---|
| p-value | 0.949 |
|---|
| Mean Difference (Final Values) | -0.55 (95% CI -17.47–16.38) |
|---|
Number of Participants Who Experienced an Adverse Event (AE)
Up to approximately 28 weeks · Participants
| MK-6194 3 mg Q2W | 51 Participants |
|---|
| MK-6194 3 mg Q4W | 47 Participants |
|---|
| Placebo | 44 Participants |
|---|
Number of Participants Who Discontinued Study Treatment Due to an AE
Up to approximately 24 weeks · Participants
| MK-6194 3 mg Q2W | 9 Participants |
|---|
| MK-6194 3 mg Q4W | 5 Participants |
|---|
| Placebo | 1 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.